Literature DB >> 16699049

Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

P I Sidiropoulos, D T Boumpas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16699049      PMCID： PMC1798160          DOI： 10.1136/ard.2005.049890

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  22 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.

Authors:  Boulos Haraoui; Louise Cameron; Michèle Ouellet; Barbara White
Journal:  J Rheumatol       Date:  2006-01       Impact factor: 4.666

3.  Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.

Authors:  M E Weinblatt; E C Keystone; D E Furst; A F Kavanaugh; E K Chartash; O G Segurado
Journal:  Ann Rheum Dis       Date:  2005-11-24       Impact factor: 19.103

4.  Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

Authors:  A Finckh; J F Simard; C Gabay; P-A Guerne
Journal:  Ann Rheum Dis       Date:  2005-12-08       Impact factor: 19.103

5.  The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study.

Authors:  Axel Finckh; Julia F Simard; Jeffrey Duryea; Matthew H Liang; Jie Huang; Synove Daneel; Adrian Forster; Cem Gabay; Pierre-André Guerne
Journal:  Arthritis Rheum       Date:  2006-01

6.  Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids.

Authors:  Ruud Oerlemans; Joost van der Heijden; Josefien Vink; Ben A C Dijkmans; Gertjan J L Kaspers; Willem F Lems; George L Scheffer; Ilan Ifergan; Rik J Scheper; Jacqueline Cloos; Yehuda G Assaraf; Gerrit Jansen
Journal:  Arthritis Rheum       Date:  2006-02

7.  The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.

Authors:  Lars Erik Kristensen; Tore Saxne; Pierre Geborek
Journal:  Arthritis Rheum       Date:  2006-02

8.  Treatment continuation in patients receiving biological agents or conventional DMARD therapy.

Authors:  A Zink; J Listing; S Kary; P Ramlau; M Stoyanova-Scholz; K Babinsky; U von Hinueber; E Gromnica-Ihle; S Wassenberg; C Antoni; P Herzer; J Kekow; M Schneider; R Rau
Journal:  Ann Rheum Dis       Date:  2005-02-11       Impact factor: 19.103

9.  The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  E William St Clair; Carrie L Wagner; Adedigbo A Fasanmade; Benjamin Wang; Thomas Schaible; Arthur Kavanaugh; Edward C Keystone
Journal:  Arthritis Rheum       Date:  2002-06

10.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Authors:  Michael E Weinblatt; Edward C Keystone; Daniel E Furst; Larry W Moreland; Michael H Weisman; Charles A Birbara; Leah A Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2003-01
View more
  10 in total

1.  Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Authors:  Stephen B Hanauer
Journal:  Gut       Date:  2007-09       Impact factor: 23.059

Review 2.  Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

Authors:  Nádia Emi Aikawa; Jozélio Freire de Carvalho; Clovis Artur Almeida Silva; Eloísa Bonfá
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 3.  TNFR1 signaling kinetics: spatiotemporal control of three phases of IKK activation by posttranslational modification.

Authors:  Lauren M Workman; Hasem Habelhah
Journal:  Cell Signal       Date:  2013-04-21       Impact factor: 4.315

Review 4.  Psoriasis and Gut Microbiome-Current State of Art.

Authors:  Karina Polak; Beata Bergler-Czop; Michał Szczepanek; Kamila Wojciechowska; Aleksandra Frątczak; Norbert Kiss
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

5.  Biologic therapy for inflammatory bowel disease comes of age.

Authors:  Stephen B Hanauer
Journal:  Curr Gastroenterol Rep       Date:  2007-12

6.  Randomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNFα therapy medication.

Authors:  Angela Reid; Audrey Brady; Catherine Blake; Anne-Barbara Mongey; Douglas J Veale; Oliver FitzGerald; Tara Cusack
Journal:  BMC Musculoskelet Disord       Date:  2011-01-13       Impact factor: 2.362

7.  Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study.

Authors:  Carter Thorne; Gilles Boire; Andrew Chow; Kirsten Garces; Fang Liu; Melanie Poulin-Costello; Valery Walker; Boulos Haraoui
Journal:  Open Rheumatol J       Date:  2017-10-24

Review 8.  Oncogenic Role of Tumor Necrosis Factor α-Induced Protein 8 (TNFAIP8).

Authors:  Suryakant Niture; Xialan Dong; Elena Arthur; Uchechukwu Chimeh; Samiksha S Niture; Weifan Zheng; Deepak Kumar
Journal:  Cells       Date:  2018-12-24       Impact factor: 6.600

9.  The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.

Authors:  Chamaida Plasencia; Dora Pascual-Salcedo; Sara García-Carazo; Leticia Lojo; Laura Nuño; Alejandro Villalba; Diana Peiteado; Florencia Arribas; Jesus Díez; Maria Teresa López-Casla; Emilio Martín-Mola; Alejandro Balsa
Journal:  Arthritis Res Ther       Date:  2013-07-26       Impact factor: 5.156

10.  Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion.

Authors:  Scott A Scarneo; Antoine Mansourati; Liesl S Eibschutz; Juliane Totzke; Jose R Roques; David Loiselle; David Carlson; Philip Hughes; Timothy A J Haystead
Journal:  Sci Rep       Date:  2018-11-19       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.